Inogen, Inc (NASDAQ:INGN) EVP Matt Scribner sold 2,500 shares of Inogen stock in a transaction that occurred on Thursday, October 12th. The stock was sold at an average price of $93.88, for a total value of $234,700.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Matt Scribner also recently made the following trade(s):

  • On Monday, September 11th, Matt Scribner sold 2,500 shares of Inogen stock. The stock was sold at an average price of $103.23, for a total value of $258,075.00.
  • On Friday, August 18th, Matt Scribner sold 2,500 shares of Inogen stock. The stock was sold at an average price of $92.45, for a total value of $231,125.00.
  • On Tuesday, July 18th, Matt Scribner sold 2,500 shares of Inogen stock. The stock was sold at an average price of $94.21, for a total value of $235,525.00.

Shares of Inogen, Inc (NASDAQ INGN) opened at 94.38 on Monday. Inogen, Inc has a 52-week low of $50.24 and a 52-week high of $105.35. The stock has a market cap of $1.96 billion, a P/E ratio of 81.93 and a beta of 1.00. The firm has a 50-day moving average price of $98.26 and a 200-day moving average price of $90.98.

Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.10. Inogen had a return on equity of 12.45% and a net margin of 10.36%. The company had revenue of $64.10 million for the quarter, compared to analyst estimates of $59.99 million. During the same quarter in the prior year, the company posted $0.25 EPS. The business’s revenue for the quarter was up 17.4% compared to the same quarter last year. On average, analysts anticipate that Inogen, Inc will post $1.21 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.dailypolitical.com/2017/10/16/insider-selling-inogen-inc-ingn-evp-sells-234700-00-in-stock.html.

A number of equities analysts recently commented on the company. Piper Jaffray Companies reiterated a “hold” rating and set a $90.00 price objective on shares of Inogen in a research report on Tuesday, September 12th. Needham & Company LLC reiterated a “buy” rating and set a $108.00 price objective on shares of Inogen in a research report on Friday, September 1st. BidaskClub upgraded Inogen from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 8th. Zacks Investment Research downgraded Inogen from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 8th. Finally, J P Morgan Chase & Co lifted their price objective on Inogen to $102.00 and gave the stock an “overweight” rating in a research report on Monday, June 26th. Four investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $90.80.

Several institutional investors and hedge funds have recently modified their holdings of INGN. Ameritas Investment Partners Inc. purchased a new position in shares of Inogen in the 1st quarter worth $109,000. Schroder Investment Management Group purchased a new position in shares of Inogen in the 2nd quarter worth $132,000. Victory Capital Management Inc. raised its position in shares of Inogen by 36.1% in the 1st quarter. Victory Capital Management Inc. now owns 1,729 shares of the medical technology company’s stock worth $134,000 after buying an additional 459 shares during the period. Sei Investments Co. raised its position in shares of Inogen by 38.1% in the 2nd quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock worth $153,000 after buying an additional 443 shares during the period. Finally, Jane Street Group LLC purchased a new position in shares of Inogen in the 1st quarter worth $203,000.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.